Author

M. Flint

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. McLaine· 1 shared A. S. Bowman· 1 shared A. Vlasova· 1 shared C. F. Spiropoulou· 1 shared C. Madden· 1 shared D. A. Carter· 1 shared D. Diaz-Campos· 1 shared D. Huey· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. McLaine

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Surveillance for SARS-CoV-2 in Ohio's wildlife, companion, and agricultural animals

M. Ehrlich, C. Madden, D. McBride, J. M. Nolting, D. Huey, S. Kenney, Q. Wang, L. Saif, A. Vlasova, P. Dennis, D. Lombardi, S. Gibson, A. McLaine, S. Lauterbach, P. Yaxley, , V. L. Hale

This study tested 800 animals in Ohio for SARS-CoV-2 RNA between 2020 and 2021 but found no infections, despite high human cases during the same period.

bioRxiv · Dec 30, 2022 · PreprintMicrobiology

Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)

M. K. Lo, P. Shrivastava-Ranjan, P. Chatterjee, M. Flint, J. R. Beadle, N. Valiaeva, R. Schooley, K. Y. Hostetler, J. Montgomery, C. F. Spiropoulou

This study evaluates the antiviral activity of ODBG-P-RVn, an orally available prodrug of remdesivir, against SARS-CoV-2 and other viruses in human airway cells, showing improved efficacy compared to GS-441524.

bioRxiv · Aug 6, 2021Pharmacology & Toxicology

Sotagliflozin, a dual SGLT1/2 inhibitor, improves cardiac outcomes in a mouse model of early heart failure without diabetes

S. L. Young, L. Ryan, T. P. Mullins, M. Flint, S. E. Steane, S. L. Walton, H. Bielefeldt-Ohmann, D. A. Carter, M. E. Reichelt, L. A. Gallo

This study shows that sotagliflozin, a dual SGLT1/2 inhibitor, improves cardiac outcomes in non-diabetic mice with heart failure but not in diabetic mice with proximal tubular damage.

bioRxiv · Aug 15, 2020 · PreprintPharmacology & Toxicology